In a significant move aimed at making life-saving medical devices more accessible to the general public, the Drug Regulatory Authority of Pakistan (DRAP) has announced new price regulations for four cardiac stents. These measures were implemented following the approval of the Ministry of National Health Services, Regulations and Coordination, and in accordance with recommendations made by the National Price Fixation Committee. The revised prices are expected to contribute towards improved affordability of cardiac treatment in the country.
New Prices for Cardiac Stents:
US Promus PREMIER: Rs58,765 The DRAP has set the price of the US Promus PREMIER cardiac stent at Rs58,765. This move aims to balance the affordability of the device without compromising on its quality and effectiveness. The US Promus PREMIER stent is widely recognized for its reliability in treating cardiac conditions, and the revised price will ensure that patients can access this vital medical device at a more reasonable cost.
DESyne X2 NECSS Novolimus Drug Eluting Stent System:
Rs72,450 To address the needs of patients requiring advanced treatment options, the DRAP has fixed the price of the DESyne X2 NECSS Novolimus Drug Eluting Stent System from the US at Rs72,450. This innovative stent offers drug-eluting properties, which help prevent the re-narrowing of arteries and improve long-term patient outcomes. The revised price will make this advanced technology more affordable for individuals seeking effective cardiac interventions.
Ultimaster Sirolimus Eluting Coronary Stent System:
Rs65,507 In a bid to diversify treatment options and cater to a broader range of patients, the DRAP has set the price of the Ultimaster Sirolimus Eluting Coronary Stent System from Japan at Rs65,507. This stent system, known for its sirolimus-eluting capabilities, provides a reliable solution for individuals with coronary artery disease. By regulating its price, the authorities aim to ensure that patients have access to this high-quality medical device at a reasonable cost.
Cre8 Amphilimus Eluting Coronary Stent:
Rs53,130 To expand the available options for cardiac treatment, the DRAP has fixed the price of the Cre8 Amphilimus Eluting Coronary Stent from Turkiye/Italy at Rs53,130. This stent incorporates amphilimus-eluting technology, offering an effective solution for individuals with coronary artery blockages. The revised price will facilitate greater affordability and enable a wider patient population to benefit from this advanced medical device.
Read More: EU approves first vaccine against common respiratory virus
Enhancing Accessibility and Affordability:
By introducing these revised price regulations, the DRAP aims to improve access to critical cardiac stents for patients across Pakistan. Cardiovascular diseases are a significant health concern in the country, and ensuring affordable treatment options is crucial for saving lives and enhancing public health. The DRAP’s proactive measures demonstrate a commitment to prioritizing the well-being of citizens and striving for equitable access to quality healthcare services.
The Drug Regulatory Authority of Pakistan has taken a commendable step in addressing the issue of affordability in cardiac treatment by fixing new prices for four cardiac stents. With a focus on striking a balance between cost and quality, these measures will undoubtedly benefit numerous patients across the country. By expanding the range of available treatment options and making them more accessible, the DRAP aims to contribute to improved health outcomes and the overall well-being of the Pakistani population.
